In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice

Manuel L. Penichet, Pia Maria Challita, Seung-Uon Shin, Sharon L. Sampogna, Joseph D Rosenblatt, Sherie L. Morrison

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background and purpose: Expression of the HER2/neu proto-oncogene, a receptor-like transmembrane protein expressed at low levels on some normal cells, is markedly increased in a subset of human breast, colon, lung, and ovarian cancers. A humanized HER2/neu antibody has been tested as a therapeutic agent in several clinical trials, with promising results. We have developed a family of anti-HER2/neu fusion proteins. To evaluate the immunologic efficacy of these proteins, it is critical that tumors expressing the target antigen can grow in immunologically intact mice. Method: To produce murine tumors expressing human HER2/neu on the surface, CT26, MC38, and EL4 murine cell lines were transduced by use of a retroviral construct containing the cDNA encoding the human HER2/neu gene. Results: Histologic features and kinetics of tumor growth in subcutaneous space of the human HER2/neu-expressing cells were similar to those of the respective parental cell lines. Intravenous inoculation with these cells induced disseminated malignant disease. Flow cytometric and immmunohistochemical analyses of freshly isolated tumors revealed in vivo expression of human HER2/neu. Secretion of antigen was not detected by use of an ELISA. Conclusion: Although an antibody response against the human HER2/neu antigen was observed, this response does not affect the growth rate of the HER2/neu- expressing cells. These murine models may be useful tools for evaluation of anti-cancer therapeutic approaches that target human HER2/neu.

Original languageEnglish
Pages (from-to)179-188
Number of pages10
JournalLaboratory Animal Science
Volume49
Issue number2
StatePublished - May 12 1999
Externally publishedYes

Fingerprint

Tumors
Cells
cell lines
Cell Line
mice
Antigens
neoplasms
erbB-2 Genes
Proteins
Neoplasms
antigens
Antibodies
cells
Fusion reactions
Complementary DNA
Genes
proto-oncogenes
therapeutics
antibodies
transmembrane proteins

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. / Penichet, Manuel L.; Challita, Pia Maria; Shin, Seung-Uon; Sampogna, Sharon L.; Rosenblatt, Joseph D; Morrison, Sherie L.

In: Laboratory Animal Science, Vol. 49, No. 2, 12.05.1999, p. 179-188.

Research output: Contribution to journalArticle

Penichet, Manuel L. ; Challita, Pia Maria ; Shin, Seung-Uon ; Sampogna, Sharon L. ; Rosenblatt, Joseph D ; Morrison, Sherie L. / In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. In: Laboratory Animal Science. 1999 ; Vol. 49, No. 2. pp. 179-188.
@article{4d89a839b38e4d73852fa67a2bb95c72,
title = "In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice",
abstract = "Background and purpose: Expression of the HER2/neu proto-oncogene, a receptor-like transmembrane protein expressed at low levels on some normal cells, is markedly increased in a subset of human breast, colon, lung, and ovarian cancers. A humanized HER2/neu antibody has been tested as a therapeutic agent in several clinical trials, with promising results. We have developed a family of anti-HER2/neu fusion proteins. To evaluate the immunologic efficacy of these proteins, it is critical that tumors expressing the target antigen can grow in immunologically intact mice. Method: To produce murine tumors expressing human HER2/neu on the surface, CT26, MC38, and EL4 murine cell lines were transduced by use of a retroviral construct containing the cDNA encoding the human HER2/neu gene. Results: Histologic features and kinetics of tumor growth in subcutaneous space of the human HER2/neu-expressing cells were similar to those of the respective parental cell lines. Intravenous inoculation with these cells induced disseminated malignant disease. Flow cytometric and immmunohistochemical analyses of freshly isolated tumors revealed in vivo expression of human HER2/neu. Secretion of antigen was not detected by use of an ELISA. Conclusion: Although an antibody response against the human HER2/neu antigen was observed, this response does not affect the growth rate of the HER2/neu- expressing cells. These murine models may be useful tools for evaluation of anti-cancer therapeutic approaches that target human HER2/neu.",
author = "Penichet, {Manuel L.} and Challita, {Pia Maria} and Seung-Uon Shin and Sampogna, {Sharon L.} and Rosenblatt, {Joseph D} and Morrison, {Sherie L.}",
year = "1999",
month = "5",
day = "12",
language = "English",
volume = "49",
pages = "179--188",
journal = "Comparative Medicine",
issn = "1532-0820",
publisher = "American Association for Laboratory Animal Science",
number = "2",

}

TY - JOUR

T1 - In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice

AU - Penichet, Manuel L.

AU - Challita, Pia Maria

AU - Shin, Seung-Uon

AU - Sampogna, Sharon L.

AU - Rosenblatt, Joseph D

AU - Morrison, Sherie L.

PY - 1999/5/12

Y1 - 1999/5/12

N2 - Background and purpose: Expression of the HER2/neu proto-oncogene, a receptor-like transmembrane protein expressed at low levels on some normal cells, is markedly increased in a subset of human breast, colon, lung, and ovarian cancers. A humanized HER2/neu antibody has been tested as a therapeutic agent in several clinical trials, with promising results. We have developed a family of anti-HER2/neu fusion proteins. To evaluate the immunologic efficacy of these proteins, it is critical that tumors expressing the target antigen can grow in immunologically intact mice. Method: To produce murine tumors expressing human HER2/neu on the surface, CT26, MC38, and EL4 murine cell lines were transduced by use of a retroviral construct containing the cDNA encoding the human HER2/neu gene. Results: Histologic features and kinetics of tumor growth in subcutaneous space of the human HER2/neu-expressing cells were similar to those of the respective parental cell lines. Intravenous inoculation with these cells induced disseminated malignant disease. Flow cytometric and immmunohistochemical analyses of freshly isolated tumors revealed in vivo expression of human HER2/neu. Secretion of antigen was not detected by use of an ELISA. Conclusion: Although an antibody response against the human HER2/neu antigen was observed, this response does not affect the growth rate of the HER2/neu- expressing cells. These murine models may be useful tools for evaluation of anti-cancer therapeutic approaches that target human HER2/neu.

AB - Background and purpose: Expression of the HER2/neu proto-oncogene, a receptor-like transmembrane protein expressed at low levels on some normal cells, is markedly increased in a subset of human breast, colon, lung, and ovarian cancers. A humanized HER2/neu antibody has been tested as a therapeutic agent in several clinical trials, with promising results. We have developed a family of anti-HER2/neu fusion proteins. To evaluate the immunologic efficacy of these proteins, it is critical that tumors expressing the target antigen can grow in immunologically intact mice. Method: To produce murine tumors expressing human HER2/neu on the surface, CT26, MC38, and EL4 murine cell lines were transduced by use of a retroviral construct containing the cDNA encoding the human HER2/neu gene. Results: Histologic features and kinetics of tumor growth in subcutaneous space of the human HER2/neu-expressing cells were similar to those of the respective parental cell lines. Intravenous inoculation with these cells induced disseminated malignant disease. Flow cytometric and immmunohistochemical analyses of freshly isolated tumors revealed in vivo expression of human HER2/neu. Secretion of antigen was not detected by use of an ELISA. Conclusion: Although an antibody response against the human HER2/neu antigen was observed, this response does not affect the growth rate of the HER2/neu- expressing cells. These murine models may be useful tools for evaluation of anti-cancer therapeutic approaches that target human HER2/neu.

UR - http://www.scopus.com/inward/record.url?scp=0032890538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032890538&partnerID=8YFLogxK

M3 - Article

C2 - 10331548

AN - SCOPUS:0032890538

VL - 49

SP - 179

EP - 188

JO - Comparative Medicine

JF - Comparative Medicine

SN - 1532-0820

IS - 2

ER -